Meridian Bioscience Reports Third Fiscal Quarter 2017 Operating Results, Including Non-Cash Goodwill Impairment Charge,Declares Regular Cash Dividend, and Reaffirms Fiscal 2017 Guidance Excluding the Effect of Goodwill Impairment Charge
GENERAL HIGHLIGHTS CINCINNATI, July 27, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today: reported fiscal 2017 third quarter and first nine months net revenues of $50.1 and $151.1 million, respectively, a decrease of 1% and an increase of 1%, respectively, from the same periods of the prior fiscal year; reported third quarter operating income […]